Recent News

• 04.15.2025 - Corporate Update Conference Call
• 04.15.2025 - Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
• 12.10.2024 - Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
• 11.11.2024 - Guggenheim Securities Healthcare Innovation Conference
• 11.11.2024 - Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Recent Filings

• 04.01.2025 - 8-K Current report
• 03.31.2025 - NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
• 02.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.10.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 12.27.2024 - 8-K Current report
• 12.20.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.20.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.20.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.10.2024 - 8-K Current report
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors